Annotation Detail
Information
- Associated Genes
- FGFR2
- Associated Variants
- FGFR2 FGFR2-MGEA5
- Associated Disease
- cholangiocarcinoma
- Source Database
- CIViC Evidence
- Description
- In a single patient with this fusion in intrahepatic cholangiocarcinoma. Ponatinib treatment resulted in necrosis and shrinkage of the primary and metastatic sites and overall stable disease. However, this response did not meet criteria for RECIST partial response.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/295
- Gene URL
- https://civic.genome.wustl.edu/links/genes/22
- Variant URL
- https://civic.genome.wustl.edu/links/variants/52
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Cholangiocarcinoma
- Evidence Direction
- Supports
- Drug
- Ponatinib
- Evidence Level
- C
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 24550739
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Ponatinib | Sensitivity | true |